Alfonso Quintas-Cardama compensation by year
Foghorn Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $144,432 | $471,000 | $494,000 |
| Bonus | $110,000 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,544,374 | $135,349 | $419,605 |
| Non-equity incentive | $43,400 | $160,140 | $217,360 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $2,329 | $3,000 | $3,000 |
| Total | $1,844,535 | $769,489 | $1,133,965 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Foghorn Therapeutics Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-193928, and prior-year filings.
How this page was built: the Foghorn Therapeutics Inc. filed document, accession 0001193125-26-193928. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 119,000 | — | $7.57 |
| Option | 33,750 | — | $3.06 |
| Option | 125,000 | — | $4.37 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Foghorn Therapeutics Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Foghorn Therapeutics’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $2,361,027 |
| Steven Bellon | Chief Scientific Officer | $1,199,455 |
| Alfonso Quintas-Cardama · this page | Chief Medical Officer | $1,133,965 |
Alfonso Quintas-Cardama's compensation dossier, Foghorn Therapeutics
You have read Alfonso Quintas-Cardama's totals and holdings. The dossier adds each equity grant Foghorn Therapeutics disclosed for Alfonso Quintas-Cardama and Foghorn Therapeutics's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Foghorn Therapeutics compensation record
free company briefThis page is one person within Foghorn Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Foghorn Therapeutics's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Foghorn Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.